Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266428 · ClinicalTrials.gov registry record · Phase 1
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Ottimo Pharma Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 170
- Enrollment target
- 4
- Study locations
NCT07266428: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Ottimo Pharma Limited.
NCT07266428 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Ottimo Pharma Limited. The registered enrollment target is 170 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (14% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07266428, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Ottimo Pharma Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 170 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues. * Have radiographic scans of their tumor at baseline and during the study at regular intervals. * Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.
Conditions Studied
Interventions
- DRUG OTP-01
Study Locations (4)
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
Texas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Utah
- START Mountain Region - West Valley City
Other
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT07266428 shows while recruiting
NCT07266428 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which OTP-01 is the first listed.
NCT07266428 reports a single indexed study location in Michigan, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT07266428 about?
NCT07266428 is a clinical study titled "A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors". The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes...
What is the current status of trial NCT07266428?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 170 participants. The study started on 2025-12-17. Estimated completion is 2028-12.
What conditions does trial NCT07266428 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07266428?
The interventions under investigation include: OTP-01 (DRUG).
Who is sponsoring clinical trial NCT07266428?
This trial is sponsored by Ottimo Pharma Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266428 being conducted?
This trial has 4 study locations across Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07266428's enrollment target sits among peer trials
170 52nd of 144 higher than 93 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI